Johnson & Johnson
30-Second Executive Brief
Executive Assessment
Johnson & Johnson functions as a systemically important institution within Healthcare & Life Sciences, backed by 80% sourcing coverage, with accelerating strategic relevance.
- Maintains 1 mapped relationship across the graph
- 80% sourcing coverage across sourced relationships
- Tracked as systemically important institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Systemically Important Institution
- Sourcing Coverage
- 80%
- Ecosystem Influence
- Very High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 1
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A diversified healthcare company operating pharmaceutical and MedTech divisions, with MedTech (cardiovascular, surgery, vision, orthopaedics) accounting for more than a third of total revenue. J&J raised its FY2026 earnings guidance after a Q2 beat, driven by its Shockwave IVL cardiovascular portfolio, and submitted its Ottava soft-tissue surgical robot to the FDA for De Novo classification in January 2026, positioning it to compete with Intuitive Surgical's da Vinci platform.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentioned by C3.ai
“The Company closed 22 agreements including with Heidelberg Materials, Ford Motor Company, Johnson Johnson, Holcim, Seaspan, the U.S. Department of Agriculture, the Defense Logistics Agency, the U.S. Department of War and the U.S. Marine Corps, among others.”
SEC 8-K exhibit (0001577526-26-000119) · Sep 2, 2026
Federal contract disclosures
Department of Defense — $471,087: 4569579217!4.5MM LCP PROXIMAL FEMUR
USAspending.gov · Sep 24, 2025
Department of Veterans Affairs — $384,719: EMERGENCY PHARMACY CARVYKTI FOR RMR
USAspending.gov · Jul 31, 2026
Department of Defense — $384,087: 8511697035!OTHER MEDICAL
USAspending.gov · Oct 16, 2025
Department of Defense — $371,551: 8510228240!OTHER MEDICAL
USAspending.gov · Oct 25, 2023
Department of Defense — $371,239: 4571008411!3.5 VOLT(TM) STRAIGHT PLATE 18H/L241MM
USAspending.gov · Feb 23, 2026
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- J&J MedTech — J&J MedTech submits Ottava robotic system to FDAcompany
- Pharmaceutical Technology — J&J raises FY26 outlook following positive Q2news
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Johnson & Johnson — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Ottava's FDA submission puts J&J roughly a full product cycle behind Intuitive Surgical
33% confidenceJ&J submitted Ottava for FDA De Novo classification in January 2026, while Intuitive Surgical's da Vinci platform already has a large installed base and switching-cost moat built over two decades.
This is InsightNodes' own interpretive read: De Novo classification alone does not confer market access -- J&J will still need to build a hospital sales and training infrastructure from scratch against an incumbent with deep clinical-workflow lock-in, so Ottava's near-term commercial impact is likely to be modest even if the FDA submission proceeds smoothly; the more relevant signal for J&J's MedTech growth in the next 1-2 years remains the existing Shockwave IVL cardiovascular portfolio, not Ottava.
InsightNodes analysis of J&J Q2 2026 results and Ottava FDA submission · Aug 14, 2026
Johnson & Johnson's Timeline
A sourced, dated history of Johnson & Johnson's key moments — founding to present.
Jan 2026 · Ottava surgical robot submitted to FDA
J&J MedTech formally submitted its Ottava soft-tissue robotic surgery system to the FDA for De Novo classification, a key step toward competing with Intuitive Surgical's da Vinci system.
Jul 2026 · Q2 2026 results beat, guidance raised
J&J reported Q2 2026 revenue of approximately $25.3 billion (up 6.6% year-over-year), with MedTech revenue of $8.93 billion, and raised FY2026 EPS guidance to $11.60-$11.75.
How These Connections Evolved
How a relationship changed over time, not just its current state — sourced, dated, and traceable.
Johnson & Johnson ↔ Healthcare & Life Sciences
2010–2020 · Pre-Kenvue-spinoff sector position
J&J's position within the broader healthcare & life sciences sector predates its 2023 Kenvue consumer-health spin-off, which narrowed the company's focus to pharmaceuticals and medtech.
Now
Johnson & Johnson operates across the pharmaceutical and medical-device segments of the healthcare and life sciences industry.